Fundraising Fox

Icosavax

Seattle, US · Founded 2017 · Delaware corporation · 3 known investors

icosavax.com ↗
Biotech

Founders & leadership

CR
Charles RichardsonSenior Vice President, Technical Operations
AK
Adam K. SimpsonPresident and Chief Executive Officer
NK
Niranjan Kanesa-thasanChief Medical Officer
DA
Douglas A. HoltzmanChief Scientific Officer and Secretary
CC
Cassia CearleyTreasurer, Chief Business Officer

Board

PKPeter Kolchinsky
Peter Kolchinskyin𝕏Board directorManaging Partner at RA Capital
MM
Mark McDadeBoard director
TG
Terry GouldBoard director
EM
Eric MoessingerBoard director
JHJason Hafler
Jason HaflerinBoard directorManaging Director at Sanofi Ventures
TY
Tadataka Yamada, M.D.Chairman of the Board

Investors · 3

RA CapitalBostonvia Peter Kolchinsky · board
Sanofi VenturesCambridge · $5M
Qiming HealthcarereportedBellevue

Reported raises · per SEC filings

Form D private placements

$129.7M disclosed across 2 rounds · 2019–2021

▶$99.7MraisedApr 2021 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter KolchinskyDirector
  • Charles RichardsonExecutive Officer
  • Mark McDadeDirector
  • Terry GouldDirector
  • Adam K. SimpsonDirector, Executive Officer
  • Eric MoessingerDirector
  • Niranjan Kanesa-thasanExecutive Officer
  • Douglas A. HoltzmanExecutive Officer
  • Jason HaflerDirector
  • Cassia CearleyExecutive Officer
  • Tadataka Yamada, M.D.Director
Offering amount
$99.7M
Amount sold
$99.7M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedOct 2019 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terry GouldDirector
  • Jason HaflerDirector
  • Eric MoessingerDirector
  • Niranjan Kanesa-thasanExecutive Officer
  • Adam K. SimpsonExecutive Officer, Director
  • Mark McDadeDirector
  • Charles RichardsonExecutive Officer
  • Douglas A. HoltzmanExecutive Officer
  • Tadataka Yamada, M.D.Director
Offering amount
$51M
Amount sold
$30M
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic | Fierce Biotechfiercebiotech.com · Apr 2021Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology – GeekWiregeekwire.com · Apr 2021Icosavax raises funding to advance RSV/hMPV vaccine programmepharmaceutical-technology.com · Apr 2021Univ. of Washington spinout Icosavax raises $51M to fight viruses with computer-designed vaccines – GeekWiregeekwire.com · Oct 2019Icosavax Raises $51M in Series A Financing - FinSMEsfinsmes.com · Oct 2019Buy Icosavax Stock – ICVX Stock Quote Today & Investment Insights - Public.compublic.com

Frequently asked questions

Who are Icosavax's investors?
Icosavax's investors include RA Capital, Sanofi Ventures, Qiming Healthcare.
How much funding has Icosavax raised?
Icosavax has disclosed $129.7M raised across 2 rounds.
Where is Icosavax headquartered?
Icosavax is headquartered in Seattle, US.